Dr. Mersedeh Bahr Hosseini's lab at UCLA focuses on developing innovative treatments for patients with acute ischemic stroke, particularly those who are not eligible for standard therapies. The lab is studying how a technique called cathodal transcranial direct current stimulation (C-tDCS) can help protect brain tissue and improve blood flow by using weak electrical currents applied to the scalp. Their research aims to optimize the dosage of this non-invasive therapy to enhance its safety and efficacy, potentially transforming the approach to stroke treatment in emergency settings.

Dr. Johannes Czernin's lab at UCLA focuses on enhancing the effectiveness of treatments for advanced prostate cancer. The research primarily revolves around understanding how different genetic and immunological factors influence responses to a specific type of targeted therapy known as PSMA-RPT, which can improve survival rates but often falls short of optimal results. By analyzing tumor characteristics and immune interactions, the lab aims to develop new combination therapies that address treatment resistance and improve patient outcomes.

Dr. Douglas L. Black's lab at UCLA focuses on understanding how RNA binding proteins regulate gene expression, particularly through alternative splicing. Their research not only explores the intricate interactions between proteins and RNA but also aims to uncover the mechanisms that lead to misregulation in diseases such as neurodegeneration and cancer. By mapping binding sites of key proteins involved in splicing, they hope to enhance the ability to predict pathogenic mutations affecting gene regulation.

Dr. Xinshu Grace Xiao's lab at UCLA focuses on understanding the genetic factors related to Alzheimer's Disease (AD). The lab investigates how certain genetic variants affect post-transcriptional regulation of mRNA, particularly through the analysis of 3' untranslated regions (UTRs) and the role of RNA derived from retrotransposable elements. Their research aims to uncover new insights into the mechanisms that contribute to AD, potentially leading to innovative therapeutic strategies.

Professor Jun Chen's lab at UCLA is focused on creating innovative vascular grafts that can continuously monitor blood flow and detect issues like stenosis without invasive procedures. They are developing a new type of graft that uses advanced materials to wirelessly transmit health data in real-time, which can help improve patient outcomes after surgeries. The lab combines expertise in bioengineering, tissue engineering, and artificial intelligence to address significant challenges in vascular health management.

Dr. Peter J. Tontonoz's lab at UCLA focuses on how fat cells store and use lipids, which is important for understanding obesity and diabetes. They investigate the role of cholesterol in blood vessel inflammation and how nutrients are absorbed in the gut. Their research aims to uncover the molecular mechanisms behind these processes, potentially leading to new treatments for metabolic diseases.

Dr. Joshua Trachtenberg's lab at UCLA focuses on how visual experiences during early development influence the formation of neural circuits in the brain. They specifically investigate the development of binocular vision and the mechanisms behind visual plasticity, using advanced techniques to track neural activity in awake animals. This research not only enhances our understanding of brain development but also holds implications for therapeutic strategies to address neural circuit disruptions later in life.

Dr. Varghese John's lab at UCLA focuses on developing innovative solutions for Alzheimer's disease (AD) through gene editing. By targeting the APOE4 gene, a major genetic risk factor for AD, the lab utilizes a cutting-edge delivery system called synthetic exosomes to transport CRISPR components across the blood-brain barrier. The lab's goal is to optimize this gene-editing technique to improve cognitive function in AD models and facilitate potential clinical applications.

Dr. Sam Emaminejad's lab at UCLA focuses on developing innovative wearable technologies that monitor health and nutrition through sweat analysis. By creating devices that can non-invasively track nutrients and biomarkers, the lab aims to enhance personalized medicine, particularly for individuals with conditions like cystic fibrosis. This interdisciplinary research combines engineering with clinical applications, promising advancements in how we understand and manage health at an individual level.

Dr. Jing Wen's lab at UCLA focuses on developing innovative solutions to combat HIV, especially in infants. They are exploring a new method to deliver broadly neutralizing antibodies (bNAbs) more effectively across the blood-brain barrier to target infections and reservoirs in the central nervous system (CNS). This research is crucial for improving treatments for infants infected with HIV and reducing neurological complications related to the virus.

Dr. Holden H. Wu's lab at UCLA focuses on improving the diagnosis and treatment of liver diseases and abdominal cancers using advanced MRI technology. The team develops new non-invasive imaging techniques that help doctors distinguish between different types of liver disease and enhance real-time guidance for minimally invasive surgical procedures. This innovative research aims to reduce the need for invasive biopsies and improve patient outcomes in cancer treatment.

Dr. Ting-Ting Wu's lab at UCLA focuses on developing an innovative vaccine for Kaposi sarcoma-associated herpesvirus (KSHV), a major cause of cancer in certain populations. The lab's research aims to enhance both the antibody and T cell responses to effectively protect against KSHV infections. By creating a vaccine that improves immunity in high-risk groups, the lab aims to reduce the incidence of KSHV-related diseases, particularly in resource-limited settings and among individuals with compromised immune systems.

Dr. Yazhen Zhu's lab focuses on improving the early detection of hepatocellular carcinoma (HCC), a severe type of liver cancer. The team is developing a novel assay that uses advanced chemistry to isolate and quantify specific particles released by tumors, which could serve as better biomarkers. This approach aims to enhance the accuracy of current diagnostic methods, ultimately allowing for earlier and more successful interventions for patients at risk of HCC.